<DOC>
	<DOCNO>NCT01178645</DOCNO>
	<brief_summary>The purpose study evaluate efficacy toxicity busulfan , etoposide , cytarabine melphalan ( BuEAM ) condition autologous stem cell transplantation patient non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Study Busulfan , Etoposide , Cytarabine , Melphalan ( BuEAM ) Conditioning Autologous Stem Cell Transplantation ( ASCT ) Treat B Cell Lymphoma Except Diffuse Large B Cell Lymphoma</brief_title>
	<detailed_description>High-dose conditioning regimen commonly use patient non-Hodgkin lymphoma BEAM ( BCNU , etoposide , cytarabine , melphalan ) , BEAC ( BCNU , etoposide , cytarabine , cyclophosphamide ) , CBV ( cyclophosphamide , carmustine , etoposide ) , combination regimen total body irradiation . Three-year progression free survival patient non-Hodgkin lymphoma receive high-dose chemotherapy follow autologous stem cell rescue report 40-50 % , still unsatisfactory . Busulfan ( Bu ) -based preparative regimen , commonly use allogeneic stem cell transplantation also study autologous stem cell transplantation lymphoma . The development intravenous busulfan achieve 100 % bioavailability bypass oral route increase safety reliability generate therapeutic busulfan level , maximize efficacy . Recently , one prospective study show combination condition regimen intravenous busulfan , cyclophosphamide , etoposide find well tolerate seem effective patient aggressive non-Hodgkin lymphoma . Another prospective study patient multiple myeloma show intravenous busulfan plus melphalan condition regimen make grade 3-4 non-hematologic complication .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients highintermediate/high risk international prognostic index diagnosis salvage chemotherapysensitive relapse/refractory nonHodgkin lymphoma Patients histologically confirm B cell lymphoma except diffuse large B cell lymphoma diagnosis Patients receive therapy highdose chemotherapy stem cell transplantation Life expectation least 3 month ECOG performance status ≤ 2 Adequate hepatic function ( serum bilirubin le 2.0 mg/dL , AST ALT less three time upper normal limit ) Adequate renal function ( serum creatinine le 2.0 mg/dL ) . Adequate cardiac function ( ejection fraction ≥ 45 % MUGA scan echocardiogram ) . Adequate bone marrow function ( ANC ≥ 1,000/mm3 platelet count ≥ 75,000/mm3 ) . All patient fully informed nature purpose study inform consent give start treatment . All patient fully understand right trial abandon without disadvantage Patients central nervous system involvement lymphoma Patients positive human immunodeficiency virus Pregnant breast feed woman Young woman without pregnancy test prior treatment pregnancy test reveals positive . Young woman without reliable proper contraceptive method Man willing contraception Concurrent history neoplasm nonHodgkin life expectancy le 3 month ( except curatively treat nonmelanoma skin cancer insitu uterine cervix cancer ) . History clinically significant cardiac dysfunction ( e.g . congestive heart failure , symptomatic coronary artery disease , medically uncontrolled arrhythmia ) myocardial infarction within 12 month A psychiatric disorder mental deficiency severe make compliance treatment unlike , make informed consent impossible . Significant infection uncontrolled bleed Enrollment clinical trial within 4 week prior treatment Any preexist medical condition sufficient severity prevent full compliance study Patient willing unable obey study protocol</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>